The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy (PTF3)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background: The treatment of traumatised refugees is one of the areas within the field of psychiatry with the weakest evidence for the different types of treatment. This is a problem for both patients and doctors as well as for society.
The treatment of choice today for Post Traumatic Stress disorder (PTSD) is antidepressants from the subgroup of Selektive Serotonin Reuptake Inhibitors (SSRI), among these the drug Sertraline. The evidence for the use of these drugs as treatment for chronically complex PTSD in traumatised refugees is however very limited and a large part of the group is estimated to be insufficiently treated with this type of medicine. Venlafaxine is an antidepressant from the subgroup of dual action product which means that is works on several pathways in the brain. Among others it influences the area in the brain that is responsible for the enhanced anxiety and hyperarousal experienced by traumatised refugees and which is found to be enlarged among patients suffering from PTSD.
All together there is not sufficient evidence to conclude which type of medical and psychological treatment that is most efficient when it comes to the treatment of traumatised refugees. Also there is a lack of studies which examines social functioning and the relation between psychosocial resources and outcome from treatment. Furthermore there is a lack of knowledge of predictors of treatment outcome for the individual patients. This study seeks to produce some of this evidence.
Method: This study is expected to include approximately 150 patients randomised into two different groups. The patients are treated with Setraline or Venlafaxine depending on the group the randomised to. Patients in both groups are getting the same version of manual based Cognitive Behavioural Therapy that is specially adapted to this group of patients. The treatment period is 6-7 month. The trial endpoints are PTSD-and depression symptoms and social functioning all measured on internationally validated ratings scales.
Furthermore the study will examine the relation between expected outcome of treatment from a range of predictors and the actual treatment results for the individual patient.
Results: Altogether this study will bring forward new standards for clinical evaluation and treatment of traumatised refugees and the results are expected to be used in reference programmes/clinical guidelines.
| Condition | Intervention | Phase |
|---|---|---|
|
Post Traumatic Stress Disorder Depression |
Drug: Venlafaxine Drug: Sertraline |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy - a Randomised Clinical Study |
- Harvard Trauma Questionnaire (HTQ) [ Time Frame: Change from baseline after aprox. 6 months treatment ] [ Designated as safety issue: No ]Self administered Rating Scale
- Hopkins Symptom Check List (HSCL-25) [ Time Frame: Change from baseline after aprox. 6 months treatment ] [ Designated as safety issue: No ]
- Social Adjustment Scale Self Report (SAS-SR) short version [ Time Frame: Change from baseline after aprox. 6 months treatment ] [ Designated as safety issue: No ]
- Hamilton Depresssion Scale (17 items) [ Time Frame: Change from baseline after aprox. 6 months treatment ] [ Designated as safety issue: No ]
- Hamilton Anxiety Scale (14 items) [ Time Frame: Change from baseline after aprox. 6 months treatment ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 150 |
| Study Start Date: | April 2012 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Venlafaxine
6 months treament vith Venlafaxine (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
|
Drug: Venlafaxine
Tablets, once a day, max 375 mg day (maximal recommended dose)
Other Names:
|
|
Active Comparator: Sertraline
6 months treament vith Sertraline (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
|
Drug: Sertraline
Tablets, once a day, maximum 200 mg/day (maximum required dose)
Other Name: Sertraline
|
Detailed Description:
Please see the summary above
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients referred to treatment in Psychiatric Clinic for refugees, Psychiatric Center Ballerup between April 2012 to May 2013
- Adults (18 years or older)
- Refugees or reunified with a refugee spouse
- Symptoms of PTSD defined by ICD-10 research criterias.
- Previosly traumatized
- Motivated for treatment
- Informed consent
Exclusion Criteria:
- Psychotic disorder (ICD-10 diagnosis F2x og F30.1-F309)
- Active substance abuse (ICD-10 F1x.24-F1x.26).
- In need of acute admission to psychiatric hospital)
- No informed consent
- Pregnant women, breastfeeding women or women who wish to become pregnant within the project period.
Contacts and Locations| Contact: Charlotte K Sonne, MD | +45 38646173 | charlotte.sonne@regionh.dk |
| Contact: Jessica C Lohman, MD | + 45 38646180 | jessica.carlsson@regionh.dk |
| Denmark | |
| Psychiatric Trauma Clinic for refugees | Recruiting |
| Gentofte, Denmark, 2900 | |
| Contact: Charlotte K Sonne, MD +45 38646173 charlotte.sonne@regionh.com | |
| Contact: Jessica C Lohman, MD + 45 38646180 jessica.carlsson@regionh.dk | |
| Principal Investigator: | Charlotte K Sonne, MD | Psychiatric Center Ballerup |
More Information
No publications provided
| Responsible Party: | Charlotte Sonne, Clinical assistent, MD, Psychiatric Center Ballerup |
| ClinicalTrials.gov Identifier: | NCT01569685 History of Changes |
| Other Study ID Numbers: | PTF3 |
| Study First Received: | March 28, 2012 |
| Last Updated: | April 25, 2013 |
| Health Authority: | Denmark: Ethics Committee Denmark: Danish Dataprotection Agency Denmark: Danish Medicines Agency |
Keywords provided by Psychiatric Center Ballerup:
|
PTSD Traumatic Stress Depressions Refugees |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Behavioral Symptoms Mood Disorders Mental Disorders Anxiety Disorders Sertraline Venlafaxine Antidepressive Agents |
Psychotropic Drugs Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin Agents Physiological Effects of Drugs Antidepressive Agents, Second-Generation |
ClinicalTrials.gov processed this record on May 21, 2013